Literature DB >> 9574675

Short-term follow-up by serology of patients given antibiotic treatment for Helicobacter pylori infection.

R J Laheij1, E M Witteman, P Bloembergen, R W de Koning, J B Jansen, A L Verbeek.   

Abstract

Helicobacter pylori serology and in particular enzyme-linked immunosorbent assays for the measurement of immunoglobulin G (IgG) antibody titers form an accurate means of diagnosing H. pylori infection in patients before treatment. H. pylori serology is of limited value in monitoring treatment because of the slow decline in antibody titers. In the present study we aimed to measure the most suitable moment after antibiotic treatment at which serology should be used to monitor treatment. Sixty-four patients who had nonulcer dyspepsia and H. pylori infection and who underwent upper gastrointestinal endoscopy because of persistent dyspeptic symptoms were included in the study. H. pylori cure was confirmed by histology and culture 5 weeks after the completion of the antibiotic treatment. Serological examination was performed before therapy and at 5 weeks, 10 weeks, and 1 year after the completion of antibiotic treatment. Diagnostic performance was assessed by receiver-operating characteristic analysis. The areas under the receiver-operating characteristic curves of the H. pylori antibody titers at 5 weeks, 10 weeks, and 1 year after the completion of treatment were 0.53 (95% confidence interval [CI], 0.36 to 0.69), 0.60 (95% CI, 0.43 to 0.76), and 0.78 (95% CI, 0.63 to 0.93), respectively. The areas under the receiver-operating characteristic curves of the changes in H. pylori IgG antibody titers at 5 weeks, 10 weeks, and 1 year after the completion of treatment in comparison with the pretreatment titers were 0.85 (95% CI, 0.72 to 0.97), 0.96 (95% CI, 0.89 to 1.0), and 1.0 (95% CI, not estimable), respectively. We conclude that serology forms a useful means of monitoring treatment in patients with nonulcer dyspepsia and H. pylori infection as early as 10 weeks and maybe even sooner after the completion of treatment for the infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9574675      PMCID: PMC104798          DOI: 10.1128/JCM.36.5.1193-1196.1998

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  12 in total

1.  Antibody titres in Helicobacter pylori infection: implications in the follow-up of antimicrobial therapy.

Authors:  T U Kosunen
Journal:  Ann Med       Date:  1995-10       Impact factor: 4.709

2.  Comparison of three commercially available enzyme-linked immunosorbent assays and biopsy-dependent diagnosis for detecting Helicobacter pylori infection.

Authors:  B A van de Wouw; W A de Boer; A R Jansz; R T Roymans; A P Staals
Journal:  J Clin Microbiol       Date:  1996-01       Impact factor: 5.948

Review 3.  Review article: symptom improvement through eradication of Helicobacter pylori in patients with non-ulcer dyspepsia.

Authors:  R J Laheij; J B Jansen; E H van de Lisdonk; J L Severens; A L Verbeek
Journal:  Aliment Pharmacol Ther       Date:  1996-12       Impact factor: 8.171

4.  14C-urea breath test in C pylori gastritis.

Authors:  E A Rauws; E A Royen; W Langenberg; J V Woensel; A A Vrij; G N Tytgat
Journal:  Gut       Date:  1989-06       Impact factor: 23.059

5.  Long-term follow-up after cure of Helicobacter pylori infection with 4 days of quadruple therapy.

Authors:  J Y Lai; W A De Boer; W M Driessen; L M Geuskens
Journal:  Aliment Pharmacol Ther       Date:  1996-08       Impact factor: 8.171

6.  Long term serological surveillance after treatment of Helicobacter pylori infection.

Authors:  R A Veenendaal; A S Peña; J L Meijer; H P Endtz; M M van der Est; W van Duijn; F Eulderink; J Kreuning; C B Lamers
Journal:  Gut       Date:  1991-11       Impact factor: 23.059

7.  Serological detection of Helicobacter pylori antibodies in children and their parents.

Authors:  L M Best; S J Veldhuyzen van Zanten; P M Sherman; G S Bezanson
Journal:  J Clin Microbiol       Date:  1994-05       Impact factor: 5.948

8.  Diagnostic value of decreasing IgG, IgA, and IgM antibody titres after eradication of Helicobacter pylori.

Authors:  T U Kosunen; K Seppälä; S Sarna; P Sipponen
Journal:  Lancet       Date:  1992-04-11       Impact factor: 79.321

9.  Evaluation of a commercially available second-generation immunoglobulin G enzyme immunoassay for detection of Helicobacter pylori infection.

Authors:  H Goossens; Y Glupczynski; A Burette; C Van den Borre; J P Butzler
Journal:  J Clin Microbiol       Date:  1992-01       Impact factor: 5.948

10.  Role of Helicobacter pylori serology in evaluating treatment success.

Authors:  A Cutler; A Schubert; T Schubert
Journal:  Dig Dis Sci       Date:  1993-12       Impact factor: 3.199

View more
  1 in total

Review 1.  Evaluation of commercially available Helicobacter pylori serology kits: a review.

Authors:  R J Laheij; H Straatman; J B Jansen; A L Verbeek
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.